Skip to main content
Premium Trial:

Request an Annual Quote

TheraGenetics Lands $6M in Series A VC Funds

NEW YORK (GenomeWeb News) — TheraGenetics has raised $6 million in a Series A round of venture capital financing, the company said Tuesday.  
 
TheraGenetics CEO Richard Kivel said the funds will help expand the company’s IP position and will speed its diagnostic development.
 
The company has developed a series of diagnostics for disorders affecting the central nervous system such as schizophrenia, Alzheimer’s disease, and mood disorders.
 
Swarraton Partners led the round, which included funds from Tudor Capital, IP Group, and IP Venture Fund, which is IP Group's venture capital fund that was raised in partnership with the European Investment Fund.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.